THE APEX TIMES
Moderna schedules live webcast and conference call for second-quarter 2026 results on Friday, July 31
The Cambridge, Massachusetts biotech said it will report second-quarter 2026 financial results with a live call and webcast set for 8:00 a.m. ET.
Moderna said it will release its second-quarter 2026 financial results on Friday, July 31, 2026, and will host a live conference call and webcast the same morning.
The company, based in Cambridge, Massachusetts, scheduled the event for 8:00 a.m. ET. Investors and other participants will be able to follow the discussion via webcast, alongside the live conference call format described in the announcement.
The disclosure comes as Moderna continues operating in a competitive vaccine and therapeutics landscape, where the timing and content of quarterly updates often shape expectations for pipeline progress and financial performance.
While Moderna did not provide additional quarter-specific figures in the announcement, such calls typically serve as the venue for management to discuss reported results and key developments during the quarter, including progress on its product portfolio and operating priorities.
For shareholders, the date is also a practical marker for when the company’s latest revenue and expense picture will be made public, along with any guidance or qualitative commentary management chooses to include.
Beyond the scheduled call, details about what will be covered in the webcast, whether the company will open the floor to live questions, and any supporting materials typically associated with quarterly reporting were not included in the brief notice.
In recent years, Moderna has relied on quarterly earnings communications to pair financial disclosures with updates on clinical and regulatory milestones. How much incremental information management plans to emphasize for the July 31 call will likely become clearer as the company releases its earnings materials ahead of the event.
Investors will want to review the company’s earnings release itself, which should include the full set of financial statements, management’s discussion, and any forward-looking statements. The announcement announcing the call did not include those specifics, so the underlying performance details are not yet available from the notice alone.
Why It Matters
- The July 31 earnings event is the next scheduled opportunity for Moderna to update markets on its quarterly financial performance and operating progress.
- An early-morning call and webcast typically functions as the main platform for management’s interpretation of results, which can influence near-term sentiment.
- For investors tracking Moderna’s program and commercial trajectory, the content of management commentary may affect expectations ahead of subsequent clinical and regulatory developments.
- Because the notice does not include numbers, the full earnings release will be necessary to assess performance and any changes in outlook.
Sources
Key Facts
- Moderna said it will report second-quarter 2026 financial results on Friday, July 31, 2026.
- The company scheduled a live conference call and webcast for 8:00 a.m. ET on July 31, 2026.
- The announcement was issued from Cambridge, Massachusetts.
- The company’s communication describes the event but does not include second-quarter 2026 financial figures in the notice.
Healthcare Related
Eli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fit
The U.S. drugmaker said it will acquire Merida Biosciences in a transaction valued at $2.88 billion, a move that is drawing attention to how Lilly is expanding its pipeline and capabilities.
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.